Sorrento Therapeutics (LTS:0L85) Gross-Profit-to-Asset % : 5.74% (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Sorrento Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Sorrento Therapeutics's annualized Gross Profit for the quarter that ended in Jun. 2023 was $26.29 Mil. Sorrento Therapeutics's average Total Assets over the quarter that ended in Jun. 2023 was $458.38 Mil. Therefore, Sorrento Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was 5.74%.

Sorrento Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for Sorrento Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Gross-Profit-to-Asset % Chart

Sorrento Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

2.68

3.25

5.50

6.48

5.03

Sorrento Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															3.10	5.86	1.38	9.49	5.74

Competitive Comparison of Sorrento Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Sorrento Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sorrento Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sorrento Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Sorrento Therapeutics's Gross-Profit-to-Asset % falls into.

Sorrento Therapeutics Gross-Profit-to-Asset % Calculation

Sorrento Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2022 )	/	( (Total Assets (A: Dec. 2021 )	+	Total Assets (A: Dec. 2022 ))	/ count )
	=	29.387	/	( (694.818	+	472.84)	/ 2 )
	=	29.387	/	583.829
	=	5.03 %

Sorrento Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2023 )	/	( (Total Assets (Q: Mar. 2023 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	26.288	/	( (460.063	+	456.692)	/ 2 )
	=	26.288	/	458.3775
	=	5.74 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Sorrento Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Sorrento Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sorrento Therapeutics (LTS:0L85) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (LTS:0L85) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

SRNEQ:USA

Address

4955 Directors Place, San Diego, CA, USA, 92121

Website

https://www.sorrentotherapeutics.com

Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (LTS:0L85) Headlines

No Headlines